The Justa & Lars Honors Bob Brinker Investment Club Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Justa & Lars Honors Bob Brinker Investment Club

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: J. M. Blackburn who wrote (13395)	4/22/2000 2:53:00 AM
From: marc ultra	Read Replies (1) of 15132

OT Jim re<<<<Marc: What is your current feeling on ENMD? I've been thinking of nibbling a little at it if it retreats further. Since you ask I think it's a screaming buy. There should some very preliminary results of the PI trial of Endostatin released possibly as early as May or later in the year. Every source I have heard says there is virtually no toxicity. As to efficacy they are trying to keep things very quiet so as to coordinate any reports with the two NCI sites. However between media accounts and rumor there are clearly responders. A very lightly publicized Bloomberg report has the company noting the lack of toxicity and the fact it is showing the biological activity hoped for. Since angiogenesis inhibitors work much more slowly than chemo as they attack the tumor vasculature and not the tumor directly, I expect a more complete report later in the year. I would also note they have also started PI trials on Angiostatin and the oral 2methoxyestradiol which both attacks the tumor directly and is also an angiogenesis inhibitor. It is my understanding that if and when Angiostatin proves safe as expected one of the PII trials will be a combination of Endostatin and Angiostatin. This is the combination that cured cancer in mice. The stock has moved around with the sector and the NASDAQ lately but it is still riddled with ignorance as the same stupid questions about the drug being unstable and difficult to produce still comes up at meetings. This was due to a complete failure by BMY to take ENMD's advice in producing the angiostatin protein. Due to that failure ENMD reclaimed the rights to AS and has been making stable Recombinant human angiostatin and endostatin yeast which is being used in the current trials. Besides using Covance as a contract manufacturer they also have a deal with Chiron for large scale up of production as needed. I bought some more in the 30's last week and it represents about 20% of my financial assets. Like any high risk biotech events could happen which could cut the price 60% or more in one day but the science is incredibly good and if some good efficacy results are announced in the next few months even though it's a PI trial big things could happen very fast. When you have a drug that is non-toxic if it has any signigicant efficacy as a single agent it will also immediately become a candidate to add to conventional chemo protocols. Finally the company is receiving royalities on all sales of thalidomide by Celgene which it licensed to them. Note if you want to follow the stock raging bull is the best place tho may be going thru some personality conflicts at the moment Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next